Wake Forest University, Winston Salem, NC
Zanetta S. Lamar , Nora Fitzgerald , Jodi Michelle Palmer , Lindsey Gruber , Olga RaetskayaSolntseva , LeAnne Kennedy , Rakhee Vaidya , Kenneth Warren Zamkoff , David Duane Hurd
Background: Standard treatment for aggressive NHL (aNHL) is R-CHOP in B cell lymphomas and CHOP in T cell lymphomas. A significant proportion of patients; however, ultimately die from their disease. To improve outcomes, novel chemotherapy combinations, dosing schedules and strategies have been used. We describe 136 patients with untreated aNHL treated with infusional dose adjusted EPOCH (DA- EPOCH) chemotherapy +/- R in the first line setting. Methods: We screened 138 patients using the tumor registry. Inclusion criteria included diagnosis of aNHL and first line treatment with EPOCH +/-R given from 2005-2013. Exclusion criteria: primary CNS lymphoma and CTCL not requiring therapy. Results: 136 patients met inclusion criteria. 112 (82%) B-cell and 24 (18%) T-cell NHL. 102 (75%) patients were stage III/IV and 34 (25%) were stage I/II. The median duration of follow up was 27 months and 62 (55%) patients completed six or more cycles. The ORR was 82%. 90 patients achieved CR, (76 B-cell and 14 T-cell); 21 with PR (16 B-cell and 5 T-cell). Using Kaplan Meier estimates, RFS at 1, 3, and 5 years was 68%, 63%, and 52% with 95% CIs [0.59,0.85], [0.54,0.70], and [0.31,0.70], respectively. Of the 136 patients, 65 were dose adjusted per guidelines. 10 (7.4%) died within 30 days of completing treatment and 50 (37%) had at least one cycle of therapy delayed. From univariate logistic regression models predicting death, progression, or relapse at two years, patients with T-cell NHL had increased risk of an event [95% CI = 1.4, 8.8] compared to B-cell NHL. Dose adjustment, delay of chemotherapy, unplanned hospitalization and hematologic or non-hematologic toxicity were not associated with risk of an event with 95% CIs [0.29,1.2], [0.45,1.9], [0.37,1.5], and [0.58,2.4] respectively. In multivariate analysis, current smoking, vincristine capped and need for second line therapy were independent predictors of death or relapse. Conclusions: Our data suggests EPOCH+/-R is active in both B and T aNHL. Toxicity did not significantly delay treatment or negatively impact outcomes. Dose adjustment by nadir had no impact on outcomes.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Ryan C Lynch
2021 ASCO Annual Meeting
First Author: Laurie Helen Sehn
2023 ASCO Annual Meeting
First Author: David Lavie
2019 ASCO Annual Meeting
First Author: Walter Quan